麻豆传媒

Switching from (Remicade) was feasible and well-tolerated among patients with inflammatory bowel disease in clinical remission, according to findings presented at the European Crohn's and Colitis Organisation (ECCO) Congress.

Also at the ECCO Congress, a 6-month interim analysis of the found that the stem cell therapy darvadstrocel continued to be safe and effective in patients with Crohn's disease and complex perianal fistulas.

Motus GI received FDA clearance to market its , an endoscopy system designed to help physicians navigate challenging colonoscopies.

A study in Taiwan found that mothers with could transmit hepatitis B to their babies, but viremia was cleared after 1 year of vaccination. (Journal of Hepatology)

An Ohio man with primary sclerosing cholangitis became one of the few Black patients in the U.S. to undergo a after an old college roommate offered him part of his liver. (NBC News)

was the preferred therapy for patients with irritable bowel syndrome. (Clinical Gastroenterology and Hepatology)

Age and nutritional risk contributed to impaired for young people with Crohn's disease. (Inflammatory Bowel Diseases)

A randomized trial found fluticasone propionate oral disintegrating tablet (APT-1011) was superior to placebo in improving endoscopic and histological responses, as well as reducing dysphagia for . (Clinical Gastroenterology and Hepatology)

R. Todd Stravitz, MD, and his family's Barbara Brunckhorst Foundation gave $104 million, the to support the new Stravitz-Sanyal Institute for Liver Disease and Metabolic Health at Virginia Commonwealth University.

Comment